Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in adverse events at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in adverse events at ≥ 12 months compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in adverse events at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in adverse events at ≥ 12 months compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Proportion of participants with adverse effects ‐ measured over 8 weeks · primary Raynaud's phenomenon
It is very uncertain whether selective serotonin reuptake inhibitors changes adverse events (over 4 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Adverse events ‐ not measured · individuals with sickle cell disease and a leg ulcer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ not reported · individuals with sickle cell disease and a leg ulcer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ ovarian cyst · women with endometriosis, following complete surgical excision of lesions
It is very uncertain whether raloxifene changes adverse events ‐ ovarian cyst compared with placebo (very low certainty).
1 finding from 1 review
Adverse events within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
Adverse events: renal calculi · relatively healthy postmenopausal women
Vitamin D plus calcium showed no clear difference in adverse events: renal calculi compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events: renal calculi · white healthy postmenopausal women over 55 years
Calcium showed no clear difference in adverse events: renal calculi compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse events ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse events (participants) · people with critical limb ischaemia
Prostanoids probably leads to higher adverse events (participants) compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events WMD of · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
Antibiotics showed no clear difference in serious adverse events WMD of compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events: death · Dialysis vascular access outcomes in AVF patients with ESKD
Omega‐3 fatty acids showed no clear difference in serious adverse events: death compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events: death · dialysis vascular access outcomes in AVG patients with ESKD
Omega‐3 fatty acids showed no clear difference in serious adverse events: death compared with placebo (low certainty).
1 finding from 1 review
Cardiovascular adverse events
It is very uncertain whether silodosin changes cardiovascular adverse events compared with placebo (very low certainty).
1 finding from 1 review
Frequency of adverse events ( · People undergoing stem cell transplant with malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes frequency of adverse events ( compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Frequency of adverse events ( · People undergoing stem cell transplant with haematological malignancies
It is very uncertain whether summary of findings: Glutamine changes frequency of adverse events ( compared with placebo (very low certainty).
1 finding from 1 review